PISANÒ, CLARISSA ANNA

PISANÒ, CLARISSA ANNA  

Dipartimento di Scienze biomediche e chirurgico specialistiche (attivo dal 01/10/2012 al 31/12/2022)  

Mostra records
Risultati 1 - 12 di 12 (tempo di esecuzione: 0.016 secondi).
Titolo Data di pubblicazione Autore(i) File
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 2020 Vegas-Suarez, S.; Pisano, C. A.; Requejo, C.; Bengoetxea, H.; Lafuente, J. V.; Morari, M.; Miguel...ez, C.; Ugedo, L.
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 2018 Arcuri, Ludovico; Novello, Salvatore; Frassineti, Martina; Mercatelli, Daniela; Pisano', Clarissa... Anna; Morella, Ilaria; Fasano, Stefania; Journigan, Blair V; Meyer, Michael E; Polgar, Willma E; Brambilla, Riccardo; Zaveri, Nurulain T; Morari, Michele
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models 2020 Kamakolanu, U. G.; Meyer, M. E.; Yasuda, D.; Polgar, W. E.; Marti, M.; Mercatelli, D.; Pisano, C.... A.; Brugnoli, A.; Morari, M.; Zaveri, N. T.
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 2019 Mercatelli, D.; Bolognesi, P.; Frassineti, M.; Pisano, C. A.; Longo, F.; Shimshek, D. R.; Morari, M.
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 2019 Morari, M.; Mercatelli, D.; Brugnoli, A.; Celeghini, C.; Pisanò, Ca file con accesso da definire
NOP receptor ligands and Parkinson’s disease 2019 Mercatelli, D.; Pisano, C. A.; Novello, S.; Morari, M.
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia 2023 Pisano, C. A.; Mercatelli, D.; Mazzocchi, M.; Brugnoli, A.; Morella, I.; Fasano, S.; Zaveri, N. T....; Brambilla, R.; O'Keeffe, G. W.; Neubig, R. R.; Morari, M.
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 2018 Morari, Michele; Brugnoli, Alberto; Pisanò, Clarissa Anna; Novello, Salvatore; Caccia, Carla; Mel...loni, Elsa; Padoani, Gloria; Vailati, Silvia; Sardina, Marco
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 2020 Pisano, C. A.; Brugnoli, A.; Novello, S.; Caccia, C.; Keywood, C.; Melloni, E.; Vailati, S.; Pado...ani, G.; Morari, M.
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia 2018 Gardoni, F; Morari, M; Kulisevsky, J; Brugnoli, Alberto; Novello, S; Pisanò, CLARISSA ANNA; Cacci...a, C; Mellone, M; Melloni, E; Padoani, G; Sosti, V; Vailati, S; Keywood, C
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 2020 Brugnoli, A.; Pisano, C. A.; Morari, M.
Therapeutic potential of RGS4 blockade in movement disorders 2020 Pisanò, CLARISSA ANNA